Advertisement

Drugs

pp 1–8 | Cite as

Elagolix: First Global Approval

  • Yvette N. Lamb
AdisInsight Report
  • 84 Downloads

Abstract

Elagolix (ORILISSA™), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women. In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain associated with endometriosis. This approval was based on positive results in two replicate phase III trials; additional phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication. Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clinical development for heavy menstrual bleeding associated with uterine fibroids in the aforementioned locations. This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain associated with endometriosis.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    AbbVie Inc. Prescribing information for OrilissaTM (elagolix) tablets, for oral use. 2018. http://www.accessdata.fda.gov/. Accessed 15 Aug 2018.
  2. 2.
    Ng J, Chwalisz K, Carter DC, et al. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–51.CrossRefPubMedGoogle Scholar
  4. 4.
    AbbVie. AbbVie receives US FDA approval of ORILISSA™ (elagolix) for the management of moderate to severe pain associated with endometriosis. 2018. https://news.abbvie.com/. Accessed 15 Aug 2018.
  5. 5.
    Abbott. Abbott and Neurocrine announce global agreement to develop and commercialize elagolix for the treatment of endometriosis [media release] 16 Jun 2010. http://www.abbott.com
  6. 6.
    Neurocrine Biosciences Inc. Neurocrine biosciences reports third quarter 2010 results [media release] 28 Oct 2010. http://www.neurocrine.com
  7. 7.
    Neurocrine Biosciences Inc. Form 10-K. 2015. https://www.sec.gov/. Accessed 7 Aug 2018.
  8. 8.
    Winzenborg I, Nader A, Polepally AR, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018.  https://doi.org/10.1007/s40262-018-0629-6.PubMedGoogle Scholar
  9. 9.
    Ng J, Salem A, Carter D, et al. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females. Clin Pharmacol Ther. 2016;99(Suppl 1):S54–5.Google Scholar
  10. 10.
    Ng J, Salem A, Carter D, et al. Effect of the coadministration of ketoconazole on the pharmacokinetics and safety of elagolix in healthy premenopausal females. Clin Pharmacol Ther. 2016;99(Suppl 1):S55.Google Scholar
  11. 11.
    Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Acs N, O’Brien C, Jiang P, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a phase 2, randomized controlled study. J Endometr Pelvic Pain Disord. 2015;7(2):56–62.Google Scholar
  14. 14.
    Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Carr B, Giudice L, Dmowski WP, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometr Pelvic Pain Disord. 2013;5(3):105–15.Google Scholar
  16. 16.
    Diamond MP, Carr B, Dmowski WP, et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363–71.CrossRefPubMedGoogle Scholar
  17. 17.
    AbbVie, Neurocrine Biosciences Inc. AbbVie announces positive topline results from phase 3 study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 21 Feb 2018.
  18. 18.
    AbbVie. AbbVie announces positive topline results from second phase 3 study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 13 Mar 2018.
  19. 19.
    AbbVie. AbbVie announces positive topline results from phase 3 extension study evaluating investigational elagolix in women with uterine fibroids [media release]. http://www.abbvie.com. Accessed 22 Aug 2018.
  20. 20.
    Stewart E, Owens C, Duan WR, et al. Elagolix alone and with add-back decreases heavy menstrual bleeding in women with uterine fibroids. Conference Abstract. 2017.Google Scholar
  21. 21.
    Simon JA, Stewart EA, Owens C, et al. Elagolix treatment in women with heavy menstrual bleeding-associated with uterine fibroids: Efficacy and safety results from a phase 2b study. Fertil Steril. 2017;108(3 Suppl):e26–7.CrossRefGoogle Scholar
  22. 22.
    Diamond M, Soliman AM, Gao J, et al. Elagolix improves quality of life in women with heavy menstrual bleeding associated with uterine fibroids: evidence from a phase 2b randomized trial. Fertil Steril. 2017;108(3 Suppl):e27.CrossRefGoogle Scholar
  23. 23.
    Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017;108(1):152–60.e4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations